NEW YORK (TheStreet) -- CHANGE IN RATINGS
upgraded at BMO to Outperform. Company should be able to resolve its supply-chain issues and the stock appears to be attractively valued.
upgraded at Baird from Neutral to Outperform. $27 price target. Company should see organic growth, given improved refinery utilization and stable vehicle markets.
upgraded at FBR from Underperform to Market Perform. $39 price target. RSH deal would make strategic sense.
initiated at Barclays with an Equal Weight rating and $88 price target. 2010 and 2011 EPS estimates set at $3.34 and $3.47, respectively.
upgraded at Stifel from Hold to Buy. $27 price target. Company likely to bid for UAUA.
upgraded at Baird from Neutral to Outperform. $88 price target. Dealer channel destocking is over and the company faces easy near-term comparisons.
Church & Dwight
downgraded at UBS from Buy to Neutral. $70 price target. Valuation call, as the stock is already pricing in mid-teens earnings growth.
upgraded at BofA/Merrill to Buy from Underperform as there could be a substantial upside to earnings. Price target surged to $22 from $10.
upgraded at BofA/Merrill to Buy from Underperform on improving US outlook. Price target surged to $65 from $35. 2010 EPS estimate improved to $2.20.
upgraded at Baird from Neutral to Outperform. $17 price target. Recent checks point to lead-time and price increases.
upgraded at Deutsche from Hold to Buy. Foodservice and EU markets are slowly improving. $51 price target.
upgraded at Baird from Neutral to Outperform. $54 price target. Company should benefit from an improved macroeconomic outlook.
upgraded at Baird from Neutral to Outperform. $82 price target. New order booking are growing and prospect lists have also increased. (In related news: Stephanie Link, Director of Research for Action Alerts Plus, explains why she is a
fan of Joy Global
in this video.)
upgraded at Barclays to Equal Weight from Underweight on positive near term wafer fundamentals. Price target increased to $7. 2010 and 2011 EPS estimates raised to 43 cents and 55 cents, respectively.
downgraded at UBS from Neutral to Sell. $10 price target. Recent wood price strength is likely not sustainable.
upgraded at Deutsche from Sell to Hold. $11 price target. RRI merger leaves the company fairly valued.
upgraded at Baird from Neutral to Outperform. $91 price target. Industrial production growth has increased and commercial vehicle markets have stabilized.
downgraded at Barclays to Equal Weight from Overweight on valuation. Price target raised to $2 from $1.60. 2010 and 2011 EPS estimates lifted to 7 cents and 13 cents, respectively.
upgraded at BMO from Market Perform to Outperform. $70 price target. Company is spending on its Goldsboro plant, which will increase production by 30%.
upgraded at Deutsche from Hold to Buy. Company should benefit from better foodservice and EU sales. $16 price target.
upgraded at Goldman to Neutral. Company should be able to take more market share from BSX. $45 price target.
upgraded at Jefferies from Hold to Buy. $49 price target. Competitive recall has improved the risk/reward.
downgraded at UBS from Buy to Neutral. Valuation call.
STOCK COMMENTS / EPS CHANGES
added to Conviction Buy List at Goldman. EBITDA can grow through 20121, given higher truck demand in the U.S. and China.
numbers raised at Goldman through 2013. Sprycel sales could help drive growth. Neutral rating and new $27 price target.
estimates lowered at Goldman through 2013. Company is expected to lose further market share. Sell rating and $6 price target.
price target higher at BofA/Merrill. CAT price target jumped to $75 from $70 as a recent dealer survey suggests higher revenue. Estimates raised through 2012. Maintain Buy rating.
estimates were boosted through 2011 at FBR Capital Markets. Checks show that spring sales are strong. Outperform rating and $18 price target.
estimates, target boosted at Goldman. Shares of CMI now seen reaching $75. Estimates also raised, as the company should benefit from higher truck production. Buy rating.
estimates boosted at Oppenheimer through 2011. PC channel checks show healthy demand. Outperform rating.
price target raised at Barclays to $57 from $55 on solid earnings expectations. 2010 EPS estimate maintained at $3.57. Reiterate Overweight rating.
numbers cut at UBS through 2011. Generic skelaxin will cut into near-term results. Buy rating and $13.50 price target.
estimates, target upped at Goldman. Shares of MDT now seen reaching $49. Estimates also boosted, as the company can gain further market share from BSX. Market Perform rating.
numbers boosted at Goldman through 2012. Company is seeing a lower tax rate and will likely buyback stock. Neutral rating and new $17 price target.
numbers boosted at Goldman. Shares of UPS now seen reaching $77. Estimates were also raised, because of higher volume expectations. Buy rating.
estimates, target boosted at UBS. Shares of VFC now seen reaching $92. Estimates also increased, as positive sales trends could drive above-consensus results. Buy rating.
This article was written by a staff member of TheStreet.com.